By Senator Galvano

21-00525A-17 20171472

A bill to be entitled

An act relating to medicinal cannabis research and education; creating s. 1004.4351, F.S.; providing a short title; providing legislative intent; defining terms; establishing the Coalition for Medicinal Cannabis Research and Education within the H. Lee Moffitt Cancer Center and Research Institute, Inc.; providing a purpose for the coalition; establishing the Medicinal Cannabis Research and Education Board to direct the operations of the coalition; providing for the appointment of board members; providing for terms of office, reimbursement for certain expenses, and the conduct of meetings of the board; authorizing the board to appoint a coalition director; prescribing the duties of the coalition director; requiring the board to advise specified entities and officials regarding medicinal cannabis research and education in this state; requiring the board to annually adopt a Medicinal Cannabis Research and Education Plan; providing requirements for the plan; requiring the board to issue an annual report to the Governor and the Legislature by a specified date; specifying responsibilities of the H. Lee Moffitt Cancer Center and Research Institute, Inc.; providing an effective date.

2526

27

28

29

1

2

3

4

5

6 7

8

9

10

11

12

13

1415

1617

18

1920

21

22

23

24

WHEREAS, cannabis, also known as marijuana, is produced from the cannabis plant, which produces a resin containing psychoactive compounds called cannabinoids, in addition to other

21-00525A-17 20171472

compounds found in plants, such as terpenes and flavonoids, and WHEREAS, cannabis is a controlled substance and is

classified as a Schedule I agent, a drug with a high potential for abuse, with no scientific evidence for medical use, and

WHEREAS, the United States Food and Drug Administration has not approved the use of cannabis as a treatment for any medical condition, and

WHEREAS, clinical trials conducted on medicinal cannabis are limited, and researchers must file an Investigational New Drug application with the United States Food and Drug Administration, obtain a Schedule I license from the United States Drug Enforcement Administration, and obtain approval from the National Institute on Drug Abuse to conduct clinical drug research with cannabis in the United States, and

WHEREAS, due to the limited number of clinical studies on the medicinal use of marijuana, there is little or no unbiased data available to support the determination of safe and effective dosages of marijuana for specific illnesses, and

WHEREAS, a significant number of Americans are seeking relief from pain and other medical symptoms through the use of cannabis, including cancer patients, patients suffering from refractory pain, and pediatric patients with refractory epilepsy, and

WHEREAS, the electorate of Florida has enshrined in the State Constitution the right to obtain and use marijuana for medicinal purposes, NOW, THEREFORE,

Be It Enacted by the Legislature of the State of Florida:

21-00525A-17 20171472

Section 1. Section 1004.4351, Florida Statutes, is created to read:

1004.4351 Medicinal cannabis research and education.-

- (1) SHORT TITLE.—This section shall be known and may be cited as the "Medicinal Cannabis Research and Education Act."
 - (2) LEGISLATIVE INTENT.—The Legislature finds that:
- (a) The present state of knowledge concerning the use of cannabis to alleviate pain and treat illnesses is limited because permission to perform clinical studies on cannabis is difficult to obtain, with access to research-grade cannabis so restricted that little or no unbiased studies have been performed.
- (b) Under the State Constitution, cannabis is available for the treatment of certain debilitating medical conditions.
- (c) Additional clinical studies are needed to ensure that the residents of this state obtain the correct dosing, formulation, route, modality, frequency, quantity, and quality of cannabis for specific illnesses.
- (d) An effective medicinal cannabis research and education program would mobilize the scientific, educational, and medical resources that presently exist in this state to determine the appropriate and best use of cannabis to treat illness.
- (3) DEFINITIONS.—As used in this section, unless the context clearly indicates otherwise, the term:
- (a) "Board" means the Medicinal Cannabis Research and Education Board.
- (b) "Coalition" means the Coalition for Medicinal Cannabis Research and Education.
 - (c) "Marijuana" or "medicinal cannabis" has the same

89

90

91

92

93

94

95

96

97

98

99

100101

102

103

104105

106

107

108

109

110111

112113

114

115

116

21-00525A-17 20171472

meaning as provided in s. 29, Art. X of the State Constitution.

(4) COALITION FOR MEDICINAL CANNABIS RESEARCH AND EDUCATION.—

- (a) There is established within the H. Lee Moffitt Cancer Center and Research Institute, Inc., the Coalition for Medicinal Cannabis Research and Education. The purpose of the coalition is to conduct rigorous scientific research; provide education; disseminate research; and to guide policy for the adoption of a statewide policy on ordering and dosing practices for the medicinal use of cannabis. The coalition shall be physically located at the H. Lee Moffitt Cancer Center and Research Institute, Inc.
- (b) The Medicinal Cannabis Research and Education Board is established to direct the operations of the coalition. The board shall be composed of seven members appointed by the chief executive officer of the H. Lee Moffitt Cancer Center and Research Institute, Inc. Board members must have experience in a variety of scientific and medical fields, including, but not limited to, oncology, neurology, psychology, pediatrics, nutrition, and addiction. Members shall be appointed to 4-year terms and may be reappointed to serve additional terms. The chair shall be elected by the board from among its members to serve a 2-year term. The board shall meet no less than semiannually, at the call of the chair or, in his or her absence or incapacity, the vice chair. Four members constitute a quorum. A majority vote of the members present is required for all actions of the board. The board may prescribe, amend, and repeal a charter governing the manner in which it conducts its business. A board member shall serve without compensation but is

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141142

143

144

145

21-00525A-17 20171472

entitled to be reimbursed for travel expenses by the coalition or the organization he or she represents in accordance with s. 119 112.061.

- (c) The coalition shall be administered by a coalition director who shall be appointed by and serve at the pleasure of the board. The coalition director shall, subject to the approval of the board:
 - 1. Propose a budget for the coalition.
- 2. Foster the collaboration of scientists, researchers, and other appropriate personnel in accordance with the coalition's charter.
- 3. Identify and prioritize the research to be conducted by the coalition.
- 4. Prepare the Medicinal Cannabis Research and Education Plan for submission to the board.
- $\underline{\text{5. Apply for grants to obtain funding for research}}$ conducted by the coalition.
 - 6. Perform other duties as determined by the board.
- (d) The board shall advise the Board of Governors, the State Surgeon General, the Governor, and the Legislature with respect to medicinal cannabis research and education in this state. The board shall explore methods of implementing and enforcing medicinal cannabis laws in relation to cancer control, research, treatment, and education.
- (e) The board shall annually adopt a plan for medicinal cannabis research, known as the "Medicinal Cannabis Research and Education Plan," which must be in accordance with state law and coordinate with existing programs in this state. The plan must include recommendations for the coordination and integration of

151

152

153154

155

156

157

158

159

160

21-00525A-17 20171472

medical, nursing, paramedical, community, and other resources

connected with the treatment of debilitating medical conditions,

research related to the treatment of such medical conditions,

and education.

- (f) By February 15 of each year, the board shall issue a report to the Governor, the President of the Senate, and the Speaker of the House of Representatives on research projects, community outreach initiatives, and future plans for the coalition.
- (5) RESPONSIBILITIES OF THE H. LEE MOFFITT CANCER CENTER
 AND RESEARCH INSTITUTE, INC.—The H. Lee Moffitt Cancer Center
 and Research Institute, Inc., shall allocate staff, information,
 and assistance, as the coalition's budget permits, to assist the
 board in fulfilling its responsibilities.

Section 2. This act shall take effect July 1, 2017.